Company
Ferrer
Ferrer has 21 drugs tracked on RxWires: 4 post-market, 9 in Phase 3, 1 in Phase 2/3, 6 in Phase 2, 1 in Phase 1/2.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Torasemide Prolonged Release (loop diuretic) | Post-Market | Hypertension |
| ciclopirox | Post-Market | Dermatomycoses |
| Moxifloxacin | Post-Market | Community-acquired Pneumonia |
| torasemide-PR | Post-Market | Compensated Heart Failure |
| Pridopidine | Phase 3 | Amyotrophic Lateral Sclerosis |
| ozenoxacin 1% cream | Phase 3 | Impetigo |
| FAB122 | Phase 3 | Amyotrophic Lateral Sclerosis |
| Cardiovascular Polypill | Phase 3 | Myocardial Infarction |
| Ozenoxacin | Phase 3 | Impetigo |
| FDC | Phase 3 | Myocardial Infarction |
| Nasal Spray | Phase 3 | Covid19 |
| Gelatin tannate (GT) + oral rehydration solution (ORS) + Zinc supplementation | Phase 3 | Diarrhea |
| Citicoline | Phase 3 | Acute Stroke |
| Chlorpheniramine Maleate 0.4% Nasal Spray | Phase 2/3 | COVID-19 |
| Cardiovascular Fixed Dose Combination Pill AAR | Phase 2 | Hypertension |
| GF-001001-00 | Phase 2 | Secondarily Infected Traumatic Lesions |
| Combination pill | Phase 2 | Hypertension |
| arasertaconazole nitrate | Phase 2 | Vulvovaginal Candidiasis |
| Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril) | Phase 2 | Elevated LDL Cholesterol |
| FNP-223 | Phase 2 | Progressive Supranuclear Palsy |
| FAB117-HC | Phase 1/2 | Acute Traumatic Spinal Cord Injury |
Latest
No recent events.
Follow Ferrer on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.